Dr. Melita Irving on the Clinical Trial Landscape Post COVID-19
Findacure hosted its first-ever Virtual Rare Disease Showcase last week from 17th – 19th November and invited Dr. Melita Irving to speak on a panel, which was led by Findacure CEO, Dr. Rick Thompson, who is another member of our impressive consortium.
Dr. Melita Irving looked to address the following concerns during her insightful panel session, “Revolutionising the clinical trial landscape post COVID-19”:
- What the future of rare disease clinical trials looks like
- How clinical trialists can respond to the challenges that COVID imposed on us all whilst still finding a way to increase patient engagement in vital clinical research
- How we can address the challenge of generating the evidence needed for ultra-rare, genetic conditions that new diagnostic techniques are increasingly uncovering – and more!
Watch the recording of her Virtual Rare Disease Showcase breakout session and let us know what you think on Twitter and Facebook! Melita was joined by Healx CMO, Tony Hall, PSR Orphan Experts founder, Christa Van Kan and Associate Professor of Molecular and Medical Genetics, Penny Hogarth.
